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Najjar et al. find that the Bcr-Abl inhibitor
ponatinib is also a dual RIPK1 and RIPK3
inhibitor with cytoprotective properties in
RIPK1- and RIPK3-driven cell death, both
in vitro and during inflammatory
pathology in vivo. The authors further
outline strategies to generate ponatinib-
based selective RIPK1 inhibitors.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
RIPK1 and RIPK3, two closely related RIPK family
members, have emerged as important regulators of
pathologic cell death and inflammation. In the current
work, we report that the Bcr-Abl inhibitor and anti-
leukemia agent ponatinib is also a first-in-class dual
inhibitor of RIPK1 and RIPK3. Ponatinib potently
inhibited multiple paradigms of RIPK1- and RIPK3-
dependent cell death and inflammatory tumor necro-
sis factor alpha (TNF-a) gene transcription. We
further describe design strategies that utilize the po-
natinib scaffold to develop two classes of inhibitors
(CS and PN series), each with greatly improved
selectivity for RIPK1. In particular, we detail the
development of PN10, a highly potent and selective
‘‘hybrid’’ RIPK1 inhibitor, capturing the best proper-
ties of two different allosteric RIPK1 inhibitors, pona-
tinib and necrostatin-1. Finally, we show that RIPK1
inhibitors from both classes are powerful blockers
of TNF-induced injury in vivo. Altogether, these find-
ings outline promising candidate molecules and
design approaches for targeting RIPK1- and RIPK3-
driven inflammatory pathologies.
INTRODUCTION
Receptor interacting protein kinases (RIPKs) are a family of
Ser/Thr and Tyr kinases with important roles in inflammation
and innate immunity. The kinase activities of RIPK1 and RIPK3
were found to be critical for the activation of necroptotic cell
death pathway by multiple stimuli, including tumor necrosis fac-1850 Cell Reports 10, 1850–1860, March 24, 2015 ª2015 The Authortor alpha (TNF-a) family of cytokines, interferons (IFNs), and Toll-
like receptor (TLR) ligands (Christofferson and Yuan, 2010; Van-
langenakker et al., 2012). Importantly, RIPK1 and RIPK3 kinases
have been implicated in a variety of pathologic settings that
currently lack effective therapies, including stroke, myocardial
infarction, retinal injuries, lethal systemic inflammatory response
syndrome (SIRS) and chronic gut and skin inflammation, and
acute pancreatitis (Linkermann and Green, 2014).
We have previously described the development of necrosta-
tins, a class of efficient small molecule inhibitors of necroptosis
(Figure 1A) (Degterev et al., 2005, 2008). Importantly, an opti-
mized analog of necrostatin-1, 7-Cl-O-Nec-1 (used throughout
this paper and referred to as Nec-1), displayed unusually exclu-
sive selectivity toward RIPK1 kinase and lacked necroptosis
inhibitory activity in the absence of RIPK1 (Christofferson et al.,
2012; Dillon et al., 2014). Structurally, this inhibitor, as well as
other necrostatins, was found to stabilize an unusual inactive
aC-Glu-out/DLG-out conformation of RIPK1 characterized by
the large movement of the aC helix (aC-out) from the active state
in conjunction with the inactive conformation of the DLG motif
(Figure 1B) (Xie et al., 2013). DFG (Asp-Phe-Gly) (or DLG in a sub-
set of kinases, like RIPK1) is a highly conserved tripeptide motif
present in most human kinases, which changes from the inactive
‘‘DXG-out’’ conformation to the active ‘‘DXG-in’’ state, where
Asp is aligned with other residues in the active center and is
involved inMg2+ binding. In addition, Nec-1was found to interact
exclusively with the DLG-out ‘‘back’’ pocket of RIPK1 without
contacts in the more redundant ATP binding site, likely explain-
ing its unusually high degree of selectivity. On the other hand,
extensive structure-activity relationship (SAR) analysis of
Nec-1 and other necrostatins revealed that even small changes
to these molecules led to the robust loss of activity and failed to
identify clear directions to significantly increase affinity of these
moderately potent (e.g., cellular IC50 of 7Cl-O-Nec-1 = 210 nM)s
Figure 1. Inhibition of Necroptosis and RIPK1 Kinase by Ponatinib
(A) Structures of necrostatins.
(B) Comparison of Glu-in/DLG-out (red, PDB: 4NEU) and Glu-out/DLG-out (blue, PDB: 4ITH) conformations of RIPK1 kinase reveals movement of aC helix.
Movement of aChelix is indicated by black arrow. Position of Nec-1 inGlu-out/DLG-out structure is shown (Nec-1, green). Ionic bond betweenGlu63 and Lys45 in
Glu-in conformation is indicated.
(C) Ponatinib inhibits recombinant RIPK1 and RIPK3 kinases in vitro. Two-mM kinases were used in the in vitro 32P autophosphorylation assay. Nec-1 only in-
hibited RIPK1, while Gleevec lacked activity against both kinases.
(D) Gleevec does not inhibit necroptosis. FADD-deficient Jurkat cells were treated with 10-ng/ml human TNF-a in the presence of 11 point dose ranges of
Ponatinib and Gleevec for 24 hr.
(E) Ponatinib inhibits TNF-induced cell death in the presence of 100-nM TAK1 inhibitor 5z-7-oxozeaenol. MEFs were stimulated with 10-ng/ml mouse TNF-awith
5z-7 for 24 hr to induce RIPK1-dependent apoptosis. To induce RIPK3-dependent necroptosis, cells were additionally treated with 50-mMzVAD.fmk. Inhibition of
cell death by indicated concentrations of ponatinib, Nec-1, and RIPK3 inhibitor GSK-872 was determined. Cell viability data are presented as mean ± SD.
See also Figure S1.molecules (Choi et al., 2012; Jagtap et al., 2007; Teng et al.,
2005, 2007, 2008). Furthermore, necrostatins could have phys-
ical limitations on maximal robustness due to the small size of
the molecules and an energy penalty due to the loss of a strong
Glu/Lys interaction in aC-Glu-out conformation (Figure 1B).
These shortcomings prompted us to explore additional ways
to target RIPK1 that would capture the excellent selectivity of ne-
crostatins while achieving significant increases in activity.
RESULTS
Discovery of Ponatinib as the First-in-Class Dual
Inhibitor of RIPK1 and RIPK3
Weobserved that Glu-in/DLG-out conformation of RIPK1 closely
resembles that of Abl (Zhou et al., 2011) (Figure S1A). Based on
this similarity, we screened small panel type 2 tyrosine kinase in-Cellhibitors, many of which display potent activity against Abl kinase.
The screen identified two molecules, ponatinib and DCC-2036,
that efficiently attenuated necroptosis (Figure S1B). Subsequent
in vitro experiments showed that both ponatinib and DCC-2036
inhibited not only RIPK1, but also RIPK3 and another member of
RIPK family RIPK2 (Canning et al., personal communication),
identifying them as the first reported pan-RIPK1/RIPK2/ RIPK3
inhibitors (Table 1). Both molecules efficiently inhibited RIPK1-
and RIPK3-dependent necroptosis in TNFa-stimulated FADD-
deficient Jurkat cells with activity of ponatinib exceeding that
of Nec-1 (Figure S1B; Table 1). DCC-2036 displayed much
poorer (>10-fold lower) cellular activity than ponatinib. We
confirmed the in vitro activity of ponatinib by showing inhibition
of RIPK1 and RIPK3 in a 32P autophosphorylation assay (Deg-
terev et al., 2008) (Figure 1C) and of RIPK1 in an HTRF assay
(Maki and Degterev, 2013) (Figure S1C). As a negative control,Reports 10, 1850–1860, March 24, 2015 ª2015 The Authors 1851








IC50, nM Jurkat Cell Necroptosis Assay
(RIPK1- and RIPK3-Dependent)
Ponatinib 14a 1.6 12 34
DCC-2036 520 18 5.7 373
Nec-1 NI NI 760 210
In vitro kinase assays were performed with recombinant RIPK2 (10 ng), RIPK1, and RIPK3 (20 ng) kinases using ADP-Glo assay (Promega). For nec-
roptosis assay, human FADD-deficient Jurkat cells were stimulated with 10-ng/ml human TNF-a for 24 hr. In all cases, activity of compounds was
determined using 8-point (HEK cells), 10-point (kinases), or 11-point (necroptosis) dose response series in duplicate. Curve fitting to calculate IC50
values was performed using GraphPad software. NI, no inhibition up to 10 mM (maximal concentration in assays).
aCanning et al., personal communication.a different Abl inhibitor, Gleevec (Imatinib), neither inhibited
RIPK1 and RIPK3 kinases in vitro (Figure 1C) nor prevented nec-
roptosis (Figure 1D).
Ponatinib was also effective in other paradigms of RIPK-driven
cell death besides TNF-a-induced necroptosis. Ponatinib af-
forded potent (IC50 = 7 nM) protection of immortalized mouse
macrophages (iBMMs), undergoing TLR4-induced necroptosis
(He et al., 2011) in response to lipopolysaccharide (LPS) and
the pan-caspase inhibitor zVAD.fmk (Figure S1D). It also pro-
tected mouse embryonic fibroblasts (MEFs) stimulated with
TNF-a in the presence of the TAK1 inhibitor 5z-7-oxozeaenol
(5z-7), a combination previously reported to induce RIPK1-
dependent but RIPK3-independent apoptosis, rather than nec-
roptosis (Figure 1E) (Dondelinger et al., 2013). Notably, in both
cases, ponatinib displayed higher activity than Nec-1 and higher
and broader activity than RIPK3 inhibitor GSK-872 (Kaiser et al.,
2013), which did not inhibit RIPK1-dependent apoptosis
(Figure 1E).
Identification of RIPK1 Kinase-Selective Analogs
of Ponatinib
Despite excellent activity against RIPK1 and RIPK3 kinases, po-
natinib’s relative lack of specificity limits its utility as a probe to
dissect RIPK1- and RIPK3-dependent signaling events and rai-
ses concerns over the safety of its use as a cytoprotective agent
in clinical settings. Thus, we explored strategies to make ponati-
nib more selective by retaining elements of its scaffold that
confer high affinity toward RIPKs, while introducing modifica-
tions enhancing selectivity toward RIPK1 and/or RIPK3. We
generated a docked model of RIPK1/ponatinib based on the
recently described co-crystal structure of ponatinib with a ho-
mologous kinase RIPK2 (PDB 4C8B; Canning et al., personal
communication), which revealed potential differences in the
binding pocket of RIPK1 versus RIPK2/Abl around the central
phenyl ring of ponatinib (Ring A; Figure S2). Namely, RIPK1 con-
tains a smaller hydrophobic pocket accommodating the methyl
of RingA (Ile43, Lys45, Leu90 andMet92 [gatekeeper]; Figure 2A)
compared with Abl, RIPK2, and RIPK3, which contain a smaller
hydrophilic Thr gatekeeper, but a bulkier DFG motif (Figure 2B).
Notably, the combination of a DLG (rather than DFG) and a me-
dium-size hydrophobic gatekeeper (Met) is unique for RIPK1
based on human kinome alignment (http://kinase.com/human/
kinome/phylogeny.html). We next tested whether these differ-
ences could be exploited to achieve selectivity between RIPK1
versus Abl/RIPK2/RIPK3. We generated an analog lacking the1852 Cell Reports 10, 1850–1860, March 24, 2015 ª2015 The AuthorRing Amethyl group (CS1; Figure 2C), which showed reduced in-
hibition for all three RIPKs and Abl (Table 2), consistent with this
group making positive, but not critical, hydrophobic contacts in
the identified lipophilic pocket. Unexpectedly, bulkier substitu-
ents in this position (CS2–CS6) displayed an abrupt loss of activ-
ity against Abl, RIPK2, and RIPK3 (RIPK3 < RIPK2 < Abl), and the
tert-butyl (CS6) analog retained activity only against RIPK1 (Ta-
ble 2). To better understand the selectivity of these analogs,
profiling was performed against a panel of 90WT human kinases
using CS analogs, representing a gradual increase in the size of
Ring A’s substituent. These data (Figure 3A; Table S1) indicated
both an increase in selectivity and a general decrease in activity
with introduction of bulkier groups on Ring A, which can be ex-
pected based on the limited size of the binding pocket. CS6 dis-
played the highest selectivity against the kinase panel. In partic-
ular, it showed no inhibition of RIPK2, 670-fold lower inhibition
of phosphorylated Abl compared with ponatinib, but only 10-
fold reduction in activity against RIPK1 (Figures 3A and 3B; Table
S1). Overall, this SAR of ponatinib achieved better RIPK1 selec-
tivity, albeit with modestly reduced activity toward RIPK1.
The selectivity of CS6 for RIPK1 appeared counterintuitive
since RIPK1’s bulkier gatekeeper residue (Met) makes its pocket
more restrictive (compared with Thr of Abl/RIPK2/RIPK3).
Notably, the bulky T315I gatekeeper mutant of Abl was inhibited
60- to 70-fold less byCS5 or CS6 comparedwith ponatinib (Ta-
ble S1) and was not inhibited by these molecules in the ADPGlo
assay (data not shown), suggesting that differences in gate-
keeper size per se do not explain the selectivity of the CS series
toward RIPK1. Another possibility is that the bulkier and more
rigid Phe of the DFG (in place of Leu157 of RIPK1DLG; Figure 2B)
may prevent induced fit accommodating the Ring A with a sub-
stituent exceeding a specific size threshold. To further address
this question, we calculated the per-atom energy contribution
to binding for ponatinib and CS6 in RIPK1 and Abl using a
MM-GBSA approach (Beard et al., 2013; Hayes et al., 2011)
with local hierarchal sampling of the residue conformations in
the DXG motif, the gatekeeper residue, and the ligand atoms
(details in Experimental Procedures) (Figures 3C and S3A). The
results indeed indicated that CS6 had an energetically more
favorable fit (indicated in blue) in RIPK1 compared with Abl (indi-
cated in red). Furthermore, introduction of Phe residue (L157F
and L157F/M92T mutants of RIPK1) rendered CS6 binding to
RIPK1 energetically unfavorable (Figure S3A). To experimentally
confirm the role of the DLG, we tested the L157F mutant of
RIPK1 in a 32P autophosphorylation assay. L157F RIPK1 wass
Figure 2. Modeling Interactions of Ponatinib CS Analogs with RIPK1 and RIPK2 Kinases
(A) Ring A of ponatinib inserts into the lipophilic pocket formed by aliphatic portions of side-chains of Ile43, Lys45, Leu90, and Met92. The backside of the
molecule is aligned with the side chain of Leu157 of DLG motif.
(B) Alignment of Leu157 of RIPK1 DLG and Phe165 of RIPK2 DFG motifs. Phe165 is in close proximity with the ATP binding pocket moiety of ponatinib.
(C) Chemical structures of CS analogs of ponatinib.
See also Figure S2.inhibited poorly by all ponatinib analogs (Figure 3D). L157F/
M92T RIPK1 containing the ‘‘Abl/RIPK2/RIPK3’’ combination
of DFG/Thr gatekeeper was inhibited by ponatinib and CS4,
but no longer inhibited by CS6, similar to Abl (Figure 3D; Table 2).
Overall, these data suggested that the more flexible DLG allows
RIPK1 to accommodate larger substituents attached to the Ring
A of ponatinib, while the Met92 gatekeeper restricts the binding
pocket, leading to the reduced inhibition of RIPK1 by CS6. These
data highlighted that relatively small differences between RIPK1
and other kinases can be exploited to achieve significant gains in
selectivity; however, these gains may be limited with respect to
the entire kinome.
Inhibition of RIPK3-Dependent Cell Death by Ponatinib
Recent evidence suggest that in a number of situations, such as
stimulation with IFNs, TLR3 agonists, and infection with mouse
herpes virus lacking endogenous RIP inhibitor (vIRA), necropto-
sis may bypass RIPK1 and proceed through direct RIPK3 activa-
tion (Dillon et al., 2014; Kaiser et al., 2013; Upton et al., 2012).
Along these lines, genetic deletion of RIPK1 in MEF cells was
found to promote RIPK3-dependent cell death in response to
IFNg (Dillon et al., 2014; Kaiser et al., 2014). We confirmed that
activation of cell death in RIPK1/ MEFs by IFNg was depen-
dent on RIPK3 by demonstrating blockade of cell death by the
RIPK3 inhibitor GSK-872 (Figure S3B). Ponatinib (Figure 3E) effi-
ciently inhibited this form of cell death at10-fold lower concen-
tration comparedwith GSK-872 (Figure S3B). Importantly, inhibi-
tion of cell death was greatly reduced with CS4, and very
marginal protection was seen with CS6 (Figure 3E), consistent
with the loss of RIPK3 kinase inhibition in vitro (Table 2). Neither
Gleevec nor Nilotininb, which are potent inhibitors of Abl but do
not inhibit RIPK1 or RIPK3 (Figure 1; data not shown), inhibited
IFNg-induced cell death, excluding a role for Abl in this model
of cell death (Figure S3C). Ponatinib also displayed activity in a
second paradigm of RIPK3-specific cell death induced by
TLR3 agonist poly(I:C)/zVAD.fmk (Kaiser et al., 2013) (Figure 3F).
CS4 again displayed reduced activity, while CS6 provided onlyCellmarginal protection on par with that demonstrated by Nec-1.
Overall, these data confirmed that ponatinib can inhibit RIPK3
kinase-driven cell death and supported the selectivity of CS an-
alogs for RIPK1 over RIPK3.
Development of Nec-1/Ponatinib ‘‘Hybrid’’ Inhibitors
A comparison of the Glu-in and Glu-out conformations of RIPK1
DLG-out pocket suggested that the latter provides more space
for inhibitor binding (Figure S4A) (187 versus 209 A˚3, respec-
tively). The RIPK1,Nec-1 co-crystal structure revealed that
Nec-1 assumes a ‘‘kinked’’ conformation (Figure 1B) (Xie et al.,
2013) in the DLG-out pocket, allowing multiple specific affinity-
driving contacts within the pocket that would be precluded in a
more narrowGlu-in conformation as seen in the RIPK1/ponatinib
docked model (Figure S4B). In contrast, flat hydrophobic moi-
eties present in typical type 2 inhibitors, like ponatinib (Figure S2),
provide a good fit with the narrower Glu-in/DXG-out conforma-
tion. Thus, we hypothesized that highly selective Glu-out/DXG-
out-targeting groups, such as those present in necrostatins,
might provide an excellent complement to the current type 2 in-
hibitor scaffolds by replacing the less selective DFG pocket
binding components of current type 2 inhibitors (Figure 4A),
which may allow us to capture both high activity of inhibitors,
like ponatinib, and excellent selectivity of necrostatins.
Accordingly, we designed and synthesized a set of ponatinib/
necrostatin-1 ‘‘hybrid’’ inhibitors, which we termed the ‘‘PN’’ se-
ries. Binding site alignment of ponatinib/RIPK1 (docked model)
and Nec-1/RIPK1 (co-crystal structure) revealed that the urea
of Nec-1 and the amide of ponatinib both form hydrogen bonds
with the backbone of Asp157 of the DLG, providing a convenient
point to connect Nec-1 to Ring A of ponatinib (distance 2.7A˚;
Figure S4C). We initially designed three PN molecules (PN1-3),
which showed good docking scores by GLIDE XP (Friesner
et al., 2004). However, these molecules displayed lower activity
toward RIPK1 compared with either Nec-1 or ponatinib (Fig-
ure 4B). We speculated that the reduced activity might have re-
sulted from suboptimal geometry of the hybrids or fromReports 10, 1850–1860, March 24, 2015 ª2015 The Authors 1853













IC50, nM Jurkat Cell
Necroptosis Assay (RIPK1-
and RIPK3-Dependent)
Ponatinib 1.4 14a 1.0a 1.6 12 34
CS1 6.7 63 3.6 7.4 42 219
CS2 5.1 45 30 49 13 48
CS3 32 1400 617 2700 33 135
CS4 31 630 472 460 19 75
CS5 181.7 5096 NI NI 28 471
CS6 34000 NI NI NI 26 354
Nec-3 NI NI NI NI 840 260
Nec-1 NI NI NI NI 760 210
Nec-4 NI NI NI NI 330 80
PN10 NI 1400 1193 NI 90 10
Experiments were performed as described in Table 1. In addition, in vitro kinase assays were performed with recombinant Abl (1 ng) using ADP-Glo
assay. For RIPK2 cellular assay, human HEK cells expressing NOD2 and NFkB-SEAP reporter were stimulated for 8 hr with 1-mg/ml L18-MDP (Inviv-
ogen), followed by detection using QUANTI-Blue SEAP reagent (Invivogen). NI, no inhibition up to 10 mM (maximal concentration in assays).
aCanning et al., personal communication.incompatible conformations of the hinge in the Glu-in/DLG-out
and Glu-out/DLG-out conformations.
To determine whether the ponatinib portion of PN hybrids
made any contribution to RIPK1 binding, we next introduced
small changes to this part of the molecule. Resulting hybrids
(PN4-6) revealed a sharp SAR for the hinge-binding fragment,
suggesting that the ponatinib portion of PNs likely makes con-
tacts in the ATP pocket, but that the geometry of the hybrids still
was not optimal. Based on these data, we designed a panel of
PNs with a broader range of linkers between the ponatinib and
Nec-1 fragments. These molecules were again docked into
RIPK1 using GLIDE XP (Figure S4D) with the added constraint
that molecules form hydrogen bonds to the backbone amide of
Met95 of the hinge and at least two out of the three hydrogen
bonds observed for Nec-1 in the DLG-out pocket Val76 (back-
bone carbonyl), Leu157 (backbone amide), or Ser161 (side-chain
alcohol) (Xie et al., 2013) to ensure that the hybrid retains con-
tacts to the hinge and a bindingmode for the Nec-1 substructure
that is consistent with the crystallographic pose (<0.5 A˚). A much
smaller subset of inhibitors that produced docking poses satis-
fying these criteria was again docked without any hydrogen
bond constraints (Figure S4D). We used two independent dock-
ing calculations to ensure that we selected molecules with the
appropriate binding mode and did not bias our selection due
to the initial hydrogen bonding constraints. As a result, several
molecules assuming a binding pose in both docking experi-
ments, comparable to Nec-1/ponatinib (Figure S4E), and
displaying good docking scores (Figure S4F) were synthesized
(Figure 4B). PN12, which did not fit these criteria, was included
to further characterize the effect of the linker length on activity.
Excitingly, one molecule in this set (PN10) displayed excellent
in vitro activity against RIPK1, exceeding that of Nec-1 (Table
2). In addition, PN10 showed better activity in necroptosis as-
says than either Nec-1 (20-fold) or ponatinib (3-fold),
suggesting that we have indeed achieved a good fit for both
the ponatinib and Nec-1 fragments in PN10. Most importantly,1854 Cell Reports 10, 1850–1860, March 24, 2015 ª2015 The AuthorPN10 displayed excellent selectivity for RIPK1 in a 90 kinases
panel screen (Figures 4D and 4E). In ADPGlo and HEKBlue as-
says, some inhibition of RIPK2 was observed, but it was greatly
reduced compared with ponatinib (Nec-1 lacks activity against
RIPK2) (Table 2). Overall, these data suggested that it is possible
to take advantage of the unique properties of both Glu-out/DXG-
out inhibitors like Nec-1 (selectivity) and Glu-in/DXG-out inhibi-
tors like ponatinib (binding affinity) to develop both potent and
highly selective type 2 inhibitors of RIPK1 kinase.
Surprisingly, while PN10 showed improved in vitro and cellular
activity against RIPK1 and necroptosis compared with other ne-
crostatins, it was still a 9-fold weaker inhibitor than ponatinib
in vitro, despite 3-fold better cellular activity (Table 2). This
may reflect differences in the binding modes between necrosta-
tins, including PN10, and ponatinib. We noticed that all necros-
tatins displayed lower activity in an in vitro kinase assay
compared to cellular inhibition of necroptosis (3- to 5-fold bet-
ter IC50 in cells than in vitro) (Table 2). In contrast, ponatinib dis-
played 3-fold higher activity in vitro than in cells. We have
previously optimized the length of RIPK1’s kinase domain (re-
combinant RIPK1, amino acids 1–327) to maximize its catalytic
activity (Maki and Degterev, 2013; Maki et al., 2013) and, hence,
the kinase active Glu-in conformation. The Glu-in conformation
creates an additional energy barrier (due to the loss of a highly
conserved Glu/Lys ionic bond in the Glu-out conformation) that
must be overcome by necrostatins (Figure 1B). This is not the
case for Glu-in inhibitors like ponatinib, explaining poorer than
expected performance of necrostatins in the in vitro kinase
assay. Notably, another previously described Glu-out inhibitor,
the Abl inhibitor PD166326 (Levinson et al., 2006), was similarly
20-fold less active in vitro compared with cellular assays (Hu-
ron et al., 2003).
A potential steric clash with the bulky gatekeeper presents a
major challenge for the design of optimal type 2 inhibitors, as
demonstrated by the inability of most type 2 Abl inhibitors to effi-
ciently target the T315I gatekeeper mutant (Zhou et al., 2011).s
Figure 3. Selectivity Profiling of CS Analogs of Ponatinib
Inhibition of a diversity set of 97 kinases (90 WT kinase and 7 mutants, ScanEDGE, DiscoveRx) by 1 mM inhibitors.
(A) Selectivity scores of CS analogs. Selectivity score values reflect number of kinases inhibited by >65% (S35), >90% (S10), or 99% (S1).
(B) TreeView maps of kinase inhibition by ponatinib and CS analogs. Red circles indicate kinases that were inhibited by the molecules >65%. The diameter of the
red circle reversely corresponds to the percentage of kinase activity remaining in the presence of inhibitor (i.e., 0% indicates complete inhibition and corresponds
to the largest size of the circle). Green circles indicate kinases that were tested but were inhibited <65%. Full data are presented in Table S1.
(C) MM-GBSA energy profile analysis reveals unfavorable interactions of CS6 with Abl. Energy changes between free and bound sates of CS6 and residues in the
Abl and RIPK1 binding pockets were calculated as described in the Experimental Procedures section. Colors indicate energy changes upon small molecule
binding from favorable (blue) to unfavorable (red). Side chains of gatekeeper and DXG residues are shown.
(D) CS6 poorly inhibits M92T/L157F mutant of human RIPK1 kinase. FLAG-tagged kinases (amino acids 1–327) were expressed in HEK293T cells, immuno-
precipitated using anti-FLAG beads, and used in 32P autophosphorylation assays with indicated concentrations of ponatinib (Pon) and CS analogs.
(E) Inhibition of IFNg-induced cell death by Ponatinib. RIPK1/MEFs were treated with 10-ng/ml IFNg in the presence of indicated concentrations of Ponatinib,
CS4, and CS6 for 24 hr.
(F) Ponatinib and GSK-872 inhibit poly(I:C)-induced cell death. MEFs were treated with inhibitors, 5-mg/ml poly(I:C), and 50-mM zVAD.fmk for 24 hr. Cell viability
data are presented as mean ± SD.
See also Figure S3 and Table S1.We found that the bulky Met92 gatekeeper of RIPK1 presented a
similar challenge for RIPK1 and was likely responsible for the
lower observed activities of PN7, PN9, and PN13 against
RIPK1 in vitro and in cells (Figure 4B) than could be expected
from their high docking scores (Figure S4F). Replacing the
Met92 residue of RIPK1 with a smaller Thr residue resulted in
much better inhibition by these molecules, which was now on
par with PN10 (Figure 4F). Since a noticeable difference in inhibi-
tion of WT and M92T RIPK1 was still seen even in the case of
PN10, additional optimization of PN10 inhibitory activity through
improving the fit with the Met92 residue may be possible by
further changes to the linker connecting the necrostatin to the
hinge binding group.
Improved Inhibition of Necrosome Formation and TNF-a
Synthesis and Reduced Cytotoxicity of CS and PN
Molecules
Next, we selected CS4, CS6, and PN10 for additional analyses.
First, we sought to further establish the mode of action of these
inhibitors by evaluating inhibition of RIPK1 and RIPK3 ‘‘ne-Cellcrosome’’ complex formation using a co-IP assay in MEF cells
stimulated with TNF-a/cycloheximide/zVAD.fmk (TCZ) (Thapa
et al., 2013). All ponatinib-based inhibitors efficiently blocked
cell death in this system at substantially lower concentrations
than those required for Nec-1 (Figures 5A and 5B) and the
RIPK3 inhibitor GSK-872 (Figure S5A). Maximal protection by
ponatinib itself was somewhat weaker than by CS4, CS6, and
PN10 (60% versus 85%), likely reflecting off-target activities
of ponatinib at concentrations approaching 1 mM. In agreement
with a role for RIPK1 kinase activity in TCZ-driven necrosome
formation (Cho et al., 2009), Nec-1 efficiently blocked ne-
crosome assembly in TCZ-treated MEFs (Figure 5C). However,
necrosome assembly was not affected by two distinct RIPK3 in-
hibitors, GSK-843 andGSK-872 (Kaiser et al., 2013) (Figure S5B),
despite both molecules efficiently protecting cells from TCZ-
induced cell death (Figure S5A; data not shown), suggesting
that in TCZ-treated MEFs necrosome formation does not require
the kinase activity of RIPK3. CS4, CS6, and PN10 all efficiently
inhibited formation of necrosome complex at lower concentra-
tions compared to Nec-1 (Figure 5C). Ponatinib again displayedReports 10, 1850–1860, March 24, 2015 ª2015 The Authors 1855
Figure 4. Development of Hybrid PN RIPK1 Inhibitors
(A) General design of hybrid PN molecules, combining DLG-out Nec-1, Ring A-containing linker, and hinge-binding fragment of ponatinib.
(B) Activities of PN series of compounds. IC50 values against recombinant RIPK1 kinasewere determined using ADPGlo assay using six-point dose range (5 mM to
20 nM) of each compound. IC50 values against necroptosis were determined in in TNF-treated FADD-deficient cells. Experiments were performed independently
from those presented in Table 2F.
(C) Comparison of the binding poses of Nec-1 (from X-ray structure, PDB: 4ITH), ponatinib (from ponatinib/RIPK1 model; Figure 3) and PN10 (resulting from ‘‘un-
constrained’’ Glide docking). Interaction diagrams were generated using Maestro software. PN10 forms three of four targeted hydrogen bonds to Met95 of the
hinge and Val76/Asp156 in the DLG-out pocket.
(D and E) Selectivity of PN10 toward RIPK1. PN10 was screened against ScanEDGE panel (DiscoveRx) of 97 kinases at 1 mM, described in Figure 3. RIPK1 was
the only kinase with >99%. Some inhibition of DYRK1b (79% inhibition) was also observed. No other kinase was inhibited >65% (other kinases in the panel
indicated by green circles). Full data are presented in Table S1.
(F) PN inhibitors display increased inhibition of M92T RIPK1 mutant with Thr gatekeeper. WT and M92T mutant were expressed in 293T cells. Proteins were
immunoprecipitated using anti-FLAG (M2)magnetic beads and used in 32P autophosphorylation assay at 10 mM.Comparable amounts ofWT andmutant kinases
in kinase reactions were confirmed by western blot.
(G) Strain penalties were calculated using modified MM-GBSA algorithm for select PN hybrids based on constrained Glide docking to RIPK1. Two different
binding poses were observed for PN9 with different strain values. PN10 was the only inhibitor without strain penalty. Notably, M92T mutation eliminated strain
penalty in case of PN13, consistent with increased inhibition of this mutant in (F).
See also Figure S4 and Table S1.
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Figure 5. Inhibition of Necroptosis and Inflammation by Ponatinib Analogs
(A and B) Inhibition of TCZ-induced necroptosis in MEFs by various RIPK inhibitors. Cells were treated with 50-ng/ml mouse TNF-a, 200-ng/ml cycloheximide,
and 25-mM zVAD.fmk for 18 hr in the presence of indicated concentrations of inhibitors.
(C) Ponatinib analogs inhibit necrosome formation in TCZ-stimulated MEFs. Cells were treated with 50-ng/ml mouse TNF-a, 200-ng/ml cycloheximide, and 25-
mM zVAD.fmk for 6 hr in the presence of indicated concentrations of inhibitors, followed by RIPK3 immunoprecipitation.
(D and E) Ponatinib inhibits RIPK1-dependent TNFamRNA upregulation in FADD-deficient Jurkat (D) and iBMM (E) cells. Jurkat cells were stimulated with 10-ng/
ml human TNF-a for 8 hr in the presence of indicated concentrations of specific RIPK1 kinase inhibitor Nec-1, ponatinib, and indicated PN and CS analogs of
ponatinib. Changes in TNFmRNA relative to GAPDHwere determined by qRT-PCR. iBMMcells were stimulated with 10-ng/ml LPS and 50-mMzVAD.fmk for 7 hr.
(F and G) Ponatinib analogs block TNF-a toxicity in vivo. Survival curves are shown in (F). Reduction in TNF-induced tissue injury and inflammatory response was
confirmed by assessing the circulating levels of injury markers (AST, LDH, CK) and mouse IL-6 in (G); n = 3–5 mice per group. *p < 0.05 for TNF per inhibitors
versus TNF group.
(H and I) Ponatinib and PN10 display higher activity than Nec-1 in vivo. Survival curves are shown in (H). Reduction in TNF-induced tissue injury and inflammatory
response was confirmed by assessing the circulating levels of injury markers (AST, LDH, CK) and mouse IL-6 in (I); n = 3–6 mice per group. *p < 0.05 for TNF/
inhibitors versus TNF group, **p < 0.015 for TNF/ponatinib and TNF/PN10 groups versus TNF/Nec-1 group. Injury marker and IL6 levels data are presented as
mean ± SD.
See also Figure S5.substantial, but lower activity, consistent with weaker inhibition
of cell death. Overall, these data confirmed inhibition of RIPK1-
dependent necrosome formation as a cellular target of the pona-
tinib-based inhibitors.
Activation of cell death is not the only function of RIPK1 kinase.
It has also been found to promote synthesis of TNF-a at the
mRNA level independent of cell death regulation (Biton and
Ashkenazi, 2011; Christofferson et al., 2012; McNamara et al.,
2013). This and other cell death-independent proinflammatory
activities of RIPK1 kinase are also emerging as potentially clini-
cally relevant targets. Thus, we sought to establish whether the
activity of ponatinib-based inhibitors extends beyond cell death
regulation by RIPK1. TNF-a stimulation of Jurkat cells and LPS/
zVAD.fmk stimulation of immortalized macrophages led to
robust increase in TNF-a mRNA, inhibited by Nec-1. Ponatinib,
CS4, CS6, and PN10 again efficiently inhibited this cell death-in-
dependent function of RIPK1 kinase (Figures 5D and 5E),
revealing potentially important anti-inflammatory properties of
ponatinib and its RIPK1-selective derivatives.CellFinally, ponatinib displayed significant cytotoxicity at concen-
trations >1 mM (Figures S5C–S5E). We found that the increased
kinase selectivity of CS molecules and PN10 also translated into
substantially lower cytotoxicity (Figures S5C–S5E), improving
one of the significant limitations of ponatinib as a cytoprotective
and anti-inflammatory agent.
Inhibition of In Vivo TNF-a Toxicity by Ponatinib Analogs
To evaluate the potential therapeutic efficacy of ponatinib-based
inhibitors, we examined their ability to counteract toxicity of
TNF-a in vivo, which was previously shown to reflect activation
of necroptotic RIPK1 and RIPK3 signaling (Duprez et al., 2011).
Intraperitoneal injection of Nec-1 at 1-mg/kg dose provided sig-
nificant protection from injury and reduced circulating levels of
interleukin-6 (IL-6) and prevented death of the animals, consis-
tent with previous reports (Duprez et al., 2011; Takahashi et al.,
2012). Ponatinib completely prevented toxicity of TNF-a,
revealing for the first time the unexpected cytoprotective proper-
ties of this anti-cancer agent in vivo (Figures 5F and 5G). PN10,Reports 10, 1850–1860, March 24, 2015 ª2015 The Authors 1857
CS4, and CS6 were also fully protective at the 1-mg/kg dose
(Figures 5F and 5G). At lower 0.4-mg/kg dose, both ponatinib
and PN10 displayed significantly higher activity than Nec-1
with respect to survival and injury markers (Figures 5H and 5I).
The improved activity of PN10 over Nec-1 demonstrated that
our guided approach has indeed led to the development of
significantly improved selective in vivo inhibitor of RIPK1-depen-
dent cell death and inflammation.
DISCUSSION
RIPK1 and RIPK3 first emerged as acting in concert in activating
necroptosis (Cho et al., 2009). However, more recent genetic
and pharmacologic evidence demonstrated that these two pro-
teins may possess multiple nonoverlapping functions in the
regulation of inflammation (Cuda et al., 2014; Lukens et al.,
2013), apoptosis (Dondelinger et al., 2013), and necroptosis
(Dannappel et al., 2014; Dillon et al., 2014; Kaiser et al., 2014; Or-
ozco et al., 2014). This array of functions has inspired us and
others to pursue development of RIPK1 (Degterev et al., 2008;
Harris et al., 2013) and RIPK3 (Kaiser et al., 2013) inhibitors.
Our current finding that ponatinib dually targets RIPK1 and
RIPK3 represents a unique and important property of this mole-
cule, making it a useful tool compound to further evaluate thera-
peutic consequences of inhibiting pathologic RIPK signaling,
where multiple mechanisms of RIPK1- and RIPK3-dependent
cell death may be activated simultaneously in different cell pop-
ulations, depending on the specifics of their state or individual
regulation. The lack of selectivity and reported safety concerns
(http://www.fda.gov/safety/medwatch/safetyinformation/
safetyalertsforhumanmedicalproducts/ucm370971.htm) may
exclude broad use of ponatinib as a cytoprotective and anti-in-
flammatory agent. However, cancer-associated inflammation
could be one specific area where the ability of ponatinib to block
RIPK1 and RIPK3 could be of immediate value. Inflammatory
mediators, including cytokines, microbial PAMPSs/DAMPs,
and carcinogenic agents such as asbestos fibers, promote
tumorigenesis by contributing to an inflammatory microenviron-
ment in certain human cancers (Elinav et al., 2013). As many of
these proinflammatory agents have also been shown to activate
RIPK1 and RIPK3 kinases (Vanlangenakker et al., 2012), ponati-
nib may help reveal functions for RIPKs in cancer-associated in-
flammatory signaling and facilitate translation of these results
into clinical benefits.
The discovery of RIPK1 and RIPK3 activity of ponatinib
prompted us to expand its SAR via two different approaches
to achieve RIPK1 selective inhibitors. Our studies with the CS se-
ries revealed an unexpected induced fit mechanism for inhibition
of RIPK1. We found that increasing the size of the phenyl ring
(Ring A) substituent of ponatinib from i-propyl to t- or c-butyl
led to an abrupt ‘‘activity cliff’’ resulting in selective inhibition of
RIPK1 compared with other RIPKs and Abl (Tables 2 and S1).
While statically RIPK1 contains a more restricted Ring A pocket
as demonstrated by poor activity of ponatinib and CSmolecules
against L157F mutant of RIPK1 (Figure 3D), this paradox can be
explained by the greater plasticity or RIPK1 due to the presence
of less bulky and more conformationally flexible DLG motif that
allows RIPK1 (but not DFG kinases Abl, RIPK2 or RIPK3) to1858 Cell Reports 10, 1850–1860, March 24, 2015 ª2015 The Authoraccommodate the bulkier Ring A through induced fit. Additional
specific differences in the packing of the activation loop and ge-
ometry of the Ring A pocket likely further differentiate affinities of
ponatinib analogs toward RIPK2 and RIPK3 versus Abl as we
have observed that these kinases, unlike Abl are poorly inhibited
even by the isopropyl CS4 analog. Overall our data reveal a
possible direction for increasing selectivity of type 2 inhibitors
by taking advantage of the differential flexibility of DXG pockets.
Strikingly, only 4 of 44 (9%) DFG-motif containing ponatinib-in-
hibited kinase targets were efficiently inhibited by CS6 (>65%
at 1 mM), while this was the case for three of four (75%) non-
DFG kinases (Table S2). Thus, our findings may be particularly
applicable for targeting non-DFG kinases.
While small changes to the ponatinib scaffold represent one
direction for achieving additional activities for ponatinib-like mol-
ecules, we show that a fragment approach combining Nec-1
with the ATP pocket-binding moiety of ponatinib (e.g., PN10)
led to a much greater improvement in selectivity and cellular ac-
tivity compared with both Nec-1 and ponatinib (Table 2). Several
conclusions can be made based on the SAR of the PN series.
First, despite ponatinib (and other type 2 inhibitors) binding to
Glu-in/DXG-out kinase conformations, dictated by interactions
of its central amide group with a Glu residue in the aC helix
(Liu andGray, 2006; Zhou et al., 2011, Zhao et al., 2014), its hinge
binding fragment appears to be compatible with the Glu-out/
DLG-out conformation of RIPK1 required for Nec-1 binding
(Xie et al., 2013). It is unlikely that PN10 binds to the Glu-in/
DLG-out conformation, as this would be expected to cause a
steric clash between the Met67 residue in the aC helix of
RIPK1 and the hydantoin of Nec-1 (Figure S4B). Second, we
found that multiple PN analogs, selected using constrained
GLIDE XP docking, underperformed due to clashes with the
Met92 gatekeeper (Figure 4F). Furthermore, we calculated strain
penalties for PN analogs using a modified MM-GBSA algorithm
to understand how PN series activities can be predicted compu-
tationally. This calculation provides a cumulative index of various
strains occurring in the ligand upon constrained docking to the
target. We observed that PN10 was the only analog lacking
strain, consistent with its highest affinity (Figure 4G). Further-
more, strain of the less active analog PN13 was eliminated in
the M92T mutant of RIPK1, consistent with comparable inhibi-
tion of this mutant by PN10 and PN13 (Figure 4F). Overall, our
data suggest that structural data available for RIPK1 in combina-
tion with GLIDE XP docking and strain analysis are sufficient for
predicting RIPK1 binding properties by hybrid molecules with a
high degree of fidelity. Finally, previous data showed that
Nec-1 is a uniquely selective kinase inhibitor (Christofferson
et al., 2012), and changes to most positions of this molecule
lead to the loss of activity (Teng et al., 2005), limiting options
for further optimization. Our data identify the direction for
improving Nec-1 activity without sacrificing specificity. The
development of PN10 captured most of ponatinib’s activity
in vivo, but also provided much improved kinase selectivity,
characteristic for Nec-1. High cellular activity of PN10, its selec-
tivity toward RIPK1, and potent inhibition of TNF-a toxicity in vivo
warrant further evaluation of the therapeutic potential of this
molecule in other preclinical models of human pathology, where
the contribution of RIPK1 has been already establisheds
(Linkermann and Green, 2014). Our data with M92T RIPK1 also
indicate that steric hindrance with the Met92 gatekeeper still ex-
ists for PN10, suggesting that further improvement of this mole-
cule may be possible through finding a better fit between the
gatekeeper and Ring A of PN10. In conclusion, we wish to high-
light the potential broad applicability of this design approach to
other kinases targeted by ponatinib, with the goal of obtaining
‘‘hybrids’’ retaining PN10’s binding mode, but containing modi-




All of the reagents and chemicals were purchased from Sigma, Fisher, or VWR
unless otherwise stated. RIPK1, actin, and tubulin antibodies were purchased
from Cell Signaling Technologies; RIPK3 antibody was from ProSci.
Cell Lines
FADD-deficient Jurkat cells and HEK293T cells were purchased from ATCC.
HEKBlue cells were purchased from Invitrogen. Immortalized bone marrow-
derived macrophages (iBMM) were a gift of Dr. Kate Fitzgerald (UMass Med-
ical Center). Cells were maintained in RPMI (Invitrogen, Jurkat cells) or DMEM
(Fisher) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) and
1% antibiotic-antimycotic mix (Invitrogen). RIPK1+/+ and RIPK1/MEFs were
a kind gift of Drs. William Kaiser and Ed Mocarski (Emory University). MEFs
were cultured in DMEM supplemented with 10% FBS (Hyclone) and 1% anti-
biotic-antimycotic mix.
Animals
All animal experiments were performed with approval of the Institutional Ani-
mal Care and Use Committee of Tufts University and Fox Chase Cancer Cen-
ter. Female C57BL6/J mice (6–8 weeks old) were purchased from approved
vendor (Charles River Laboratories). Animals were housed in cages with a
light/dark cycle. All efforts were made to minimize the numbers of animals
and their suffering.
TNF-Induced Injury
To study the effect of the compounds in TNF-induced injury in mouse model,
female C57BL6/J mice were injected intraperitoneally with 100 ml of vehicle
(25% PEG400 in PBS) or the compounds (Nec-1, ponatinib, PN10, CS4, and
CS6, formulated in the above vehicle) at the doses of 1 and 0.4 mg/kg. At
15 min later, animals were injected intravenously through the tail vein with
either 5 mg per mouse of recombinant mouse TNF-a (Cell Guidance System)
or sterile PBS in a volume of 100 ml. Blood samples were collected 30 hr after
injection or earlier if moribund through submandibular bleed. Serum samples
were submitted to IDEXX laboratories for analysis of aspartate aminotrans-
ferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) levels.
IL-6 ELISA was performed using 25 ml of serum using mouse IL-6 ELISA kit
(Meso Scale Discovery). Statistical analysis was performed using Student’s t
test (GraphPad Prism 5).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
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